Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

ONO-013105 synergizes with rituximab in models of MCL and advances in phase I trial

Dec. 16, 2010

HG-829 reverses resistance to antineoplastic agents in vitro and in vivo

Dec. 16, 2010

Phase II trial of EGEN-001 in advanced ovarian cancer opens enrollment

Dec. 15, 2010

CCX-721 has antitumor effects in murine model of multiple myeloma

Dec. 15, 2010

Lilly suspends phase III trial of tasisulam in metastatic melanoma

Dec. 15, 2010

ATL-313 and dexamethasone have synergistic antitumor effect in models of multiple myeloma

Dec. 15, 2010

Zealand Pharma receives milestone payment from Helsinn Healthcare regarding ZP-1846

Dec. 14, 2010

Merck & Co. claims new inhibitors of kinesin-like protein KIF11

Dec. 14, 2010

Novel inhibitors of M-phase inducer phosphatase 3 claimed

Dec. 14, 2010

Eisai launches anticancer agent Treakisym in Japan

Dec. 14, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...